NK cells and their receptors in naive and rituximab-treated patients with anti-MAG polyneuropathy

被引:3
|
作者
Benedetti, Luana [1 ]
Facco, Monica [2 ]
Franciotta, Diego [3 ]
Dalla Torre, Chiara [4 ]
Campagnolo, Marta [4 ]
Lucchetta, Marta [4 ]
Boscaro, Elisa [2 ]
Ermani, Mario [4 ]
Del Sette, Massimo [1 ]
Berno, Tamara [2 ]
Candiotto, Laura [2 ]
Zambello, Renato [2 ]
Briani, Chiara [4 ]
机构
[1] Osp S Andrea, Dept Neurol, La Spezia, Italy
[2] Univ Padua, Dept Med DIMED, I-35100 Padua, Italy
[3] Natl Inst Neurol C Mondino, IRCCS, Lab Neuroimmunol, Pavia, Italy
[4] Univ Padua, Dept Neurosci, I-35100 Padua, Italy
关键词
Natural killer (NK) cells; CD94/NKG2A; Myelin associated glycoprotein; Anti-MAG antibodies; IgM; Monoclonal gammopathy; Rituximab; NATURAL-KILLER-CELLS; PERIPHERAL-BLOOD; MULTIPLE-SCLEROSIS; MONOCLONAL-ANTIBODY; T-CELLS; AUTOIMMUNE; NEUROPATHY; DISEASE;
D O I
10.1016/j.jns.2013.05.015
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Natural killer (NK) cells can bridge innate and acquired immunity, and play a role in autoimmunity. A few studies evaluated the distribution of NK cells and the expression of their receptors in chronic immune-mediated demyelinating polyneuropathies. We investigated NK cell distribution and NK cell receptor expression in 20 naive patients with anti-MAG polyneuropathy (MAG-PN). Methods: Using flow cytometry, we analysed NK cells and a series of NK cell receptors in the peripheral blood of patients with MAG-PN, and, as controls, in patients with chronic inflammatory demyelinating peripheral polyradiculoneuropathy (CIDP) and in healthy subjects. Six MAG-PN patients were also tested after rituximab treatment. Results: At baseline the percentage of NK cells did not differ among the groups. KIR2DL2 receptor expression in MAG-PN patients was higher, andCD94/NKG2A receptor expression in both MAG-PN and CIDP patients was lower than in healthy controls. These abnormalities did not correlate with any clinical or demographic variable. No modification was found after rituximab therapy. Conclusions: The data suggest that MAG-PN shows abnormalities in NK cell receptors that characterise other autoimmune diseases, and cannot help in differential diagnosis with CIDP. The impairment of the relevant CD94/NKG2A inhibitory pathway, which might play a central role in the development and perpetuation of MAG-PN, warrants further functional investigations. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:86 / 89
页数:4
相关论文
共 50 条
  • [31] Anti-MAG associated cerebellar ataxia and response to rituximab
    Panagiotis Zis
    Dasappaiah Ganesh Rao
    Nigel Hoggard
    Ptolemaios Georgios Sarrigiannis
    Marios Hadjivassiliou
    Journal of Neurology, 2018, 265 : 115 - 118
  • [32] Are Biological and Electrophysiological Parameters Related to the Disability of the Patients with Polyneuropathy with Anti-MAG Antibodies?
    Delmont, Emilien
    Launey, Mael
    Benaim, Charles
    Sacconi, Sabrina
    Desnuelle, Claude
    NEUROLOGY, 2009, 72 (11) : A134 - A134
  • [33] Worsening after rituximab treatment in anti-MAG neuropathy
    Broglio, L
    Lauria, G
    MUSCLE & NERVE, 2005, 32 (03) : 378 - 379
  • [34] Worsening after rituximab treatment in anti-MAG neuropathy
    Broglio, L
    Lauria, G
    JOURNAL OF NEUROLOGY, 2005, 252 : 156 - 157
  • [35] Acute neurological worsening after Rituximab treatment in patients with anti-MAG neuropathy
    Sala, Emilie
    Robert-Varvat, Florence
    Paul, Stephane
    Camdessanche, Jean-Philippe
    Antoine, Jean-Christophe
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2014, 345 (1-2) : 224 - 227
  • [36] Therapeutic options and management of polyneuropathy associated with anti-MAG antibodies
    Vallat, Jean-Michel
    Magy, Laurent
    Ciron, Jonathan
    Corcia, Philippe
    Le Masson, Gwendal
    Mathis, Stephane
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (09) : 1111 - 1119
  • [37] RETREATMENT WITH RITUXIMAB IN ANTI-MAG POLYNEUROPATHY: IS THE B-CELL-ACTIVATING FACTOR (BAFF) A NEGATIVE PROGNOSTIC FACTOR?
    Garnero, M.
    Franciotta, D.
    Briani, C.
    Campagnolo, M.
    Grandis, M.
    Fabbri, S.
    Beronio, A.
    Mancardi, G. L.
    Schenone, A.
    Benedetti, L.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2017, 22 : S19 - S19
  • [38] ANTI-MAG NEUROPATHY WITH ACUTE ONSET AND PARADOXICAL RESPONSE TO RITUXIMAB
    Cassano, Emanuele
    Iodice, Rosa
    Tozza, Stefano
    Iovino, Aniello
    Pisano, Enrica
    Dubbioso, Raffaele
    Ruggiero, Lucia
    Nolano, Maria
    Manganelli, Fiore
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2023, 28 : S15 - S16
  • [39] Long term efficacy of rituximab for IgM and anti-MAG neuropathy
    Lewis, R. A.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2008, 13 (02) : 175 - 175
  • [40] Rituximab in anti-mag associated neuropathy: A monocentric experience.
    Delarue, R
    Deau, B
    Alyanakian, MA
    Varet, BR
    Hermine, O
    BLOOD, 2004, 104 (11) : 309B - 309B